CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
dc.contributor.author | Economopoulos, T. | en |
dc.contributor.author | Psyrri, A. | en |
dc.contributor.author | Dimopoulos, M. A. | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Tsatalas, C. | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Mellou, S. | en |
dc.contributor.author | Xiros, N. | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Economopoulos, T. | en |
dc.creator | Psyrri, A. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Tsatalas, C. | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Mellou, S. | en |
dc.creator | Xiros, N. | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:53:00Z | |
dc.date.available | 2018-06-22T09:53:00Z | |
dc.date.issued | 2007 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41604 | |
dc.description.abstract | Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) improves outcomes in patients with previously untreated aggressive lymphomas. In a secondary analysis we evaluated the impact of adding rituximab to CEOP-14/CEOP-21 chemotherapy. Study Design: The trial opened in March 1999, and patients were randomly assigned to either CEOP-14 or CEOP-21. All patients enrolled from May 2002 onward received rituximab with each chemotherapy cycle, and those attaining a complete response received rituximab consolidation. Results: Complete and overall response rates in the CEOP-21 ± rituximab (N ≤ 114) and CEOP-14 ± rituximab (N ≤ 103) arms were similar, as were the overall survival (P ≤ 0.769) and time to progression distributions (P ≤ 0.969). Rituximab was shown to have a beneficial effect both on the overall survival and on the time to progression. Conclusions: Thus far, no significant improvement in outcome has been demonstrated with CEOP-14 ± rituximab versus CEOP-21 ± rituximab. However, with addition of rituximab to CEOP-21/CEOP-14, significant improvements in time to progression and overall survival were achieved. © 2007 by Lippincott Williams & Wilkins. | en |
dc.language.iso | eng | en |
dc.source | Cancer Journal | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Human | en |
dc.subject | Prednisone | en |
dc.subject | Vincristine | en |
dc.subject | 80 and over | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer growth | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Controlled clinical trial | en |
dc.subject | Diarrhea | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Mucosa inflammation | en |
dc.subject | Multicenter study | en |
dc.subject | Nausea and vomiting | en |
dc.subject | Neurotoxicity | en |
dc.subject | Neutropenia | en |
dc.subject | Recombinant granulocyte colony stimulating factor | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Cardiotoxicity | en |
dc.subject | Drug hypersensitivity | en |
dc.subject | Fever | en |
dc.subject | Liver toxicity | en |
dc.subject | Phase 3 clinical trial | en |
dc.subject | Randomized controlled trial | en |
dc.subject | Treatment outcome | en |
dc.subject | Adolescent | en |
dc.subject | B cell lymphoma | en |
dc.subject | Nonhodgkin lymphoma | en |
dc.subject | Rituximab | en |
dc.subject | Epirubicin | en |
dc.subject | Male | en |
dc.subject | Antibodies | en |
dc.subject | B-cell | en |
dc.subject | Lymphoma | en |
dc.subject | Monoclonal antibody | en |
dc.subject | Unclassified drug | en |
dc.subject | Pathology | en |
dc.subject | Treatment response | en |
dc.subject | Drug dose reduction | en |
dc.subject | Multiple cycle treatment | en |
dc.subject | Drug withdrawal | en |
dc.subject | Middle aged | en |
dc.subject | Comparative study | en |
dc.subject | Deep vein thrombosis | en |
dc.subject | Monoclonal | en |
dc.subject | Non-hodgkin | en |
dc.subject | Ceop | en |
dc.subject | T cell lymphoma | en |
dc.subject | T-cell | en |
dc.subject | Vincristine sulfate | en |
dc.subject | Aggressive non-hodgkin lymphoma | en |
dc.subject | Brain hemorrhage | en |
dc.subject | Ceop protocol 1 | en |
dc.subject | Doseintensification | en |
dc.subject | Drug dose comparison | en |
dc.subject | Mantle cell lymphoma | en |
dc.subject | Mantle-cell | en |
dc.subject | Overall survival | en |
dc.title | CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1097/PPO.0b013e3181570170 | |
dc.description.volume | 13 | |
dc.description.issue | 5 | |
dc.description.startingpage | 327 | |
dc.description.endingpage | 334 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.gnosis.orcid | 0000-0002-2195-9961|0000-0002-6801-3129 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |